-
2024-513027-16-00
4
2018-05-28
Resectable mucosal melanomas
-
2023-503469-49-00
5
2018-04-19
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
-
2024-516477-73-00
3
2018-03-07
Bladder cancer and kidney cancer
-
2023-509004-15-00
10
2018-02-20
Patients with non-small cell lung cancer (NSCLC).
-
2024-514309-73-00
5
2018-02-06
Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
-
2023-506110-43-00
9
2018-01-25
Multiple Myeloma
-
2024-510840-30-00
4
2017-12-01
Hormone Naive Prostate Cancer
-
2024-516601-23-00
5
2017-11-14
Colorectal adenomas
-
2023-507702-13-00
7
2017-09-22
Male or female patients age 12 years or older with a locally advanced
-
2024-513964-24-00
5
2017-09-14
Squamous cell carcinoma, previously untreated
Stage III, stage IVa (op
-
2023-506186-57-00
5
2017-09-04
Cancer (Future parent protocols may include other cancer that are not
-
2024-515119-23-00
9
2017-08-29
Phase Ib and Phase II part 1: HPV-16 positive recurrent or metastatic
-
2023-509169-19-00
5
2017-07-11
Advanced ALK positive non-small cell lung cancer
-
2023-506390-35-00
1
2017-04-19
Patients with Advanced Solid Tumors
-
2022-502668-20-00
9
2017-04-11
Solid tumors harboring NTRK fusion
-
2024-517489-41-00
5
2017-03-27
High-risk stage III colon cancer
-
2024-510704-37-00
5
2017-03-22
ER+/HER2- metastatic breast cancer
-
2024-513972-16-00
5
2017-01-30
- Resected tumors of sinuses or salivary glands
- Non-operable tumors
-
2024-511722-31-00
9
2016-11-29
Acute Myeloid Leukemia (AML)
-
2024-515846-18-00
7
2016-09-19
Newly diagnosed Diffuse Large B Cell Lymphoma
-
2023-505034-10-00
4
2016-08-01
Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS
-
2024-515749-40-00
5
2016-02-25
Malignant melanoma of the skin in patients with locally advanced and f
-
2022-501253-37-00
4
2016-02-02
(A) Anal Squamous Cell Carcinoma,
(B) Biliary Adenocarcinoma (gallblad
-
2024-513509-30-00
5
2016-01-11
Progressive or recurrent germ cell tumor (measurable or non-measurable